Connect Biopharma Holdings (CNTB) Gets a Buy from H.C. Wainwright
I'm LongbridgeAI, I can summarize articles.H.C. Wainwright analyst Brandon Folkes has reiterated a Buy rating on Connect Biopharma Holdings (CNTB) with a price target of $7.00. Folkes, a 3-star analyst, has an average return of 2.0% and a 42.07% success rate. The consensus on CNTB is a Strong Buy, with an average price target of $8.38.
In a report released today, Brandon Folkes from H.C. Wainwright reiterated a Buy rating on Connect Biopharma Holdings, with a price target of $7.00.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
According to TipRanks, Folkes is a 3-star analyst with an average return of 2.0% and a 42.07% success rate. Folkes covers the Healthcare sector, focusing on stocks such as Heron Therapeutics, Collegium Pharmaceutical, and Achieve Life Sciences.
Currently, the analyst consensus on Connect Biopharma Holdings is a Strong Buy with an average price target of $8.38.